2.5.2024 13:59:41 CEST | Thor Medical ASA | Additional regulated information required to be disclosed under the laws of a member state

Reference is made to the stock exchange announcements made by Thor Medical ASA (the "Company") on 21 April 2024 regarding issuance of 1,320,469 new shares to members of the board. The share issue has now been registered in the Norwegian Register of Business Enterprises and the Company's new share capital is NOK 46,971,895 dividend into 234,859,475 shares, each with a nominal value of NOK 0.20. Each share represents one vote in the Company's general meeting.

Disclosure regulation

This information is required to be disclosed under Section 5-12 of the Securities Trading Act.

Contacts

• Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.no

About Thor Medical ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’. 

To learn more, visit  www.thormedical.no.

Attachments

• Download announcement as PDF.pdf